Do we need new treatments for type 2 diabetes?

被引:0
|
作者
Gomez-Peralta, Fernando [1 ]
Abreu Padin, Cristina [1 ]
机构
[1] Hosp Gen Segovia, Unidad Endocrinol & Nutr, Segovia, Spain
来源
ENDOCRINOLOGIA Y NUTRICION | 2014年 / 61卷 / 06期
关键词
Diabetes; Future treatment; Antidiabetic drugs; Hypoglycemia; Weight;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diagnosis of type 2 diabetes mellitus encompasses multiple pathophysiological and clinical situations. Type 2 diabetes mellitus is characterized by a long and changing natural history. Personal circumstances and preferences also condition the actual effectiveness and safety of drugs used. In recent decades, modern drugs have markedly expanded and improved therapeutic options. However, their effectiveness remains limited in clinical practice. The main objective of decreasing macrovascular complications is not fully proven. Adverse events, especially hypoglycemia and weight gain, are still frequent and decrease treatment adherence. The constant loss of endogenous islet cell reserve is the main determinant of the need for intensified therapies. Current treatments have failed to improve long-term beta cell mass/function. It is desirable to move forward to obtain new drugs that offer solutions sustainable in the long term. These drugs should be able to fit the individual circumstances and preferences of patients with diabetes mellitus. (C) 2013 SEEN. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:323 / 328
页数:6
相关论文
共 50 条
  • [21] Protein ‘pre-loads’ in type 2 diabetes: what do we know and what do we need to find out?
    Christopher K. Rayner
    Jing Ma
    Karen L. Jones
    Peter M. Clifton
    Michael Horowitz
    Diabetologia, 2014, 57 : 2603 - 2604
  • [22] Protein 'pre-loads' in type 2 diabetes: what do we know and what do we need to find out?
    Rayner, Christopher K.
    Ma, Jing
    Jones, Karen L.
    Clifton, Peter M.
    Horowitz, Michael
    DIABETOLOGIA, 2014, 57 (12) : 2603 - 2604
  • [23] New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?
    Seewoodhary, Jason
    Wong, Stephen Phooi Yew
    Ekanayake, Kaharanthilaka Poojanie
    PRACTICAL DIABETES, 2015, 32 (08) : 288 - 294
  • [24] Current antidepressant treatments: what do we have and what do we need?
    Cowen, Philip J.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2012, 16 : 10 - 11
  • [25] Potential new treatments for type 2 diabetes
    Bailey, Clifford J.
    Chemistry and Industry (London), 1998, (02): : 53 - 57
  • [26] Potential new treatments for type 2 diabetes
    Bailey, CJ
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (07) : 259 - 265
  • [27] Potential new treatments for type 2 diabetes
    Bailey, CJ
    CHEMISTRY & INDUSTRY, 1998, (02) : 53 - 57
  • [28] Type 2 diabetes mellitus: New treatments
    Ascaso, Juan F.
    MEDICINA CLINICA, 2014, 143 (03): : 117 - 123
  • [29] Mediterranean diet, type 2 diabetes prevention and healthy ageing: Do we need more evidence?
    Maltese, Giuseppe
    Koufakis, Theocharis
    Kotsa, Kalliopi
    Basile, Giorgio
    Siow, Richard
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 205
  • [30] Do we need the oral glucose tolerance test to identify future cases of type 2 diabetes?
    Stern, MP
    Williams, K
    Haffner, SM
    DIABETES CARE, 2003, 26 (03) : 940 - 941